The latest financial statement is for the year ending 2026-03-31.
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -505,606 |
| Stock-based compensation | 55,724 |
| Depreciation on property and equipment | 409 |
| Non-cash lease expense | 99 |
| Accounts receivable | -986 |
| Prepaid expenses and other current assets | -8,844 |
| Income tax receivable | 2,386 |
| Other assets | -69 |
| Accounts payable | -10,252 |
| Accrued expenses | 45,000 |
| Operating lease liabilities | -99 |
| Due to roivant sciences ltd | -98 |
| Net cash used in operating activities | -407,310 |
| Purchases of property and equipment | 8 |
| Net cash used in investing activities | -8 |
| Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement | 544,194 |
| Payment of offering and private placement costs | 504 |
| Proceeds from stock options exercised | 52,066 |
| Net cash provided by financing activities | 595,756 |
| Effect of exchange rate changes on cash and cash equivalents | -299 |
| Net change in cash and cash equivalents | 188,139 |
| Cash and cash equivalents beginning of period | 713,971 |
| Cash and cash equivalents end of period | 902,110 |
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)